Let me dig deeper into the Q1 2026 earnings call transcript, release, and MD&A for details, plus more recent news.Let me read those two conference call transcripts for more recent management commentary since Q1 report.# Zoetis (ZTS) Q2 2026 Earnings Preview Report Date: August 6, 2026 (before market open) | Event: 2026Q2 Earnings Call
Investors head into this print with scar tissue. ZTS shares cratered from roughly $111 to $87 the day Q1 2026 results were released (May 7) and kept sliding to the low-$70s before stabilizing in the $74–$78 range over the past two months — a peak-to-trough decline of well over 30%, taking the stock to levels not seen in years. Ahead of tomorrow's print, sentiment ahead of the report is gloomy due to concerns about the Librela franchise and the overall companion animal business, following a very negative Q1 report that triggered a sharp stock price decline, though the bar is now considered quite low and signs of stabilization in the companion animal segment could support the shares. Wall Street currently models EPS of $1.84 and total sales growth of +1.6% for the quarter.
That $1.84 consensus would compare against adjusted diluted EPS of $1.76 and adjusted net income of $783 million that Zoetis reported for Q2 2025 — modest growth, but a sharp deceleration from the 8% organic operational revenue growth and 10% organic adjusted net income growth Zoetis delivered a year ago. This is the crux of the debate heading into the print: is the business truly stabilizing, or is the "easier comp" narrative papering over structurally slower growth?
Zoetis' Q1 2026 (reported under its newly aligned fiscal calendar) was a rare outright disappointment for a company that had compounded steadily for years. Management described a convergence of interconnected dynamics shaping decisions at the point of care: pricing in veterinary clinics continuing to rise even as clinic traffic softened, increased pet-owner price sensitivity weighing on premium preventative and chronic-care products, intensified competition in dermatology and parasiticides with more aggressive and prolonged promotional pricing from new entrants, and — critically — that new entrants were not translating into overall market expansion the way they had historically.
The headline numbers were stark: global revenue was flat on an organic operational basis, with 2% growth coming from price, offset by 2% decline in volume, and management later clarified that stripping out a one-time ~$100 million fiscal-calendar-alignment benefit, globally, we would have seen a 5% organic operational decline in the quarter. U.S. companion animal was hit hardest, down 11%, with key dermatology (Apoquel/Cytopoint) down 13% in the U.S. and Librela down 22% in the U.S., partly compounded by distributor and retail channel purchasing patterns that lagged end-market demand.
Management's response was to widen full-year guidance rather than abandon it: full-year 2026 organic operational revenue growth of 2%–5% and adjusted net income growth of 2%–6%, alongside a new cost/productivity program. They also stressed the deceleration was expected to some degree — "as we shared on the call, as we look at the balance of the year, there are a number of areas that we anticipate sequential improvement in" — largely driven by easing year-over-year comparisons rather than an actual sequential dollar ramp, since "we're not anticipating a significant uplift — an uptick between the first half and the second half. But the comps actually drive a greater and more pronounced view."
a) Is Librela/OA-Pain actually stabilizing? This is arguably the single most important line item. Management flagged in Q1 that "sequentially, Librela has stabilized in the U.S. with roughly flat growth" and that "U.S. Librela revenue increased sequentially for the first time in 6 quarters, and vet and pet owner satisfaction ratings remained stable." Investors will want to see this trend continue into Q2, especially since the OA-pain comp gets progressively easier through the year (management noted OA-pain headwinds began showing up around mid-2025).
b) Derm and Simparica competitive intensity. Apoquel/Cytopoint and the Simparica franchise absorbed the brunt of new-entrant competition in Q1. Management has been explicit it will not chase competitors down on list price — "we do not intend to reduce prices to compete in this world... unless you believe you can more than grow the market 10% taking the pricing down, you can't" — instead leaning on point-of-sale loyalty/affordability programs and targeted promotions. Watch for commentary on U.S. Simparica Trio share trends (management said puppy share, a leading indicator, remained well above overall patient share) and whether the "share stabilization near prior-year levels" story extends into Q2.
c) Distributor/retail channel normalization. Roughly $60–100 million of the Q1 shortfall was attributed to distributors and retailers under-ordering relative to sell-through amid soft end-market demand. Management called this a "demand issue" rather than a stocking anomaly and said it should not recur — "inventory level is much more about a demand issue... that will not persist". Confirmation (or contradiction) of that view will matter for the credibility of the back-half ramp.
d) Livestock — the reliable offset, with a screwworm wildcard. Livestock has been the bright spot, growing 12% organically in Q1 on strength in cattle, poultry and fish, and management guided to mid- to high-single-digit growth for livestock for the year. A confirmed New World screwworm case in Texas in June triggered a notable rally in ZTS options activity as traders positioned for potential gains following a confirmed screwworm case in Texas, with the animal health company viewed as a potential beneficiary of the disease outbreak — worth watching for any Q2 revenue contribution or updated commentary on parasiticide demand tied to the outbreak.
e) Cost discipline / margin leverage. Zoetis launched a comprehensive cost and productivity program in Q1 aimed at "a leveraged P&L in 2026 and beyond," targeting headcount, T&E, consulting/professional services and procurement — explicitly protecting field force and pipeline spend. Full-year guidance calls for adjusted cost of sales of ~28.5% of revenue and SG&A of $2.35–2.40 billion; gross margin, ex-FX, actually improved 140bps in Q1, so investors will watch whether that execution continues.
f) Pipeline/launch updates. Watch for early-experience readouts on Lenivia/Portela (long-acting OA-pain launches in EU/Canada) — management said on the Stifel call they'd "share more" at Q2 earnings — and any timing updates on Cytopoint Plus (long-acting Cytopoint, expected approval end of 2026, launch in 2027) and the Neogen animal-genomics acquisition, which is expected to close in H2 2026.
g) FY2026 guidance: reiterate, narrow, or cut? Current guidance stands at revenue of $9.68–$9.96 billion (2%–5% organic growth) and adjusted EPS of $6.85–$7.00. Given management's repeated emphasis that H2 outperformance is largely a function of easier comps rather than sequential dollar acceleration, any signal of further deterioration in derm/parasiticide competitive intensity or macro/consumer pressure would be a red flag for the guide; conversely, a reaffirmation with modest Librela/livestock upside would likely be read as a "low bar cleared" positive.
Zoetis ended Q1 2026 with $1.94 billion in cash, $9.0 billion in long-term debt, and $1.8 billion remaining on its buyback authorization, having repurchased $606 million of stock in Q1 alone. The company issued $2.0 billion of convertible notes in December 2025 (partly to fund buybacks) and refinanced senior notes in August 2025, leaving leverage manageable and covenant compliance intact. With the stock trading near multi-year lows, management has signaled continued willingness to lean into repurchases opportunistically.
Bear case: The Q1 collapse revealed that Zoetis' core moats (Apoquel/Cytopoint in derm, Simparica in parasiticides) are more exposed to price-driven competition and a non-expanding market than previously assumed, and consumer-driven softness in vet visits could persist for "1 or 2 years, if not longer" as one analyst put it on the Q1 call — with the biggest new pipeline blockbusters (renal, oncology, cardiology) not contributing meaningfully until 2027–2028.
Bull case: Management's own data show sequential (if modest) stabilization in Librela and parasiticide share, livestock remains a double-digit growth engine with a possible screwworm tailwind, diagnostics continues to post double-digit growth, cost actions are already showing up in margins, and expectations have been reset so low (stock down ~35%+ from pre-Q1 levels) that even an in-line-to-slightly-better quarter with confirmed stabilization trends could trigger relief buying.
The bar for tomorrow's report is low after Q1's shock and the subsequent guide-down, but the market will be laser-focused on trend lines rather than absolute levels: sequential improvement (or lack thereof) in Librela and Simparica/derm share, evidence that distributor/retail ordering has normalized, confirmation of livestock strength, and management's tone on whether the 2%–5% full-year revenue growth guide remains intact. Given consensus is calling for only modest EPS growth ($1.84 vs. $1.76 a year ago) and roughly flat-to-low-single-digit sales growth, this is a "show me" quarter — the real test is whether Zoetis can demonstrate the back-half acceleration embedded in its own guidance is achievable, or whether competitive and macro pressures in companion animal are proving more durable than management currently expects.